> X0707 D LIVE 0001497504 PLx Pharma Inc. 8285 EL RIO STREET SUITE 130 HOUSTON TX TEXAS 77054 (713) 842-1249 DELA WARE Dipexium Pharmaceuticals, Inc. Dipexium Pharmaceuticals, LLC Corporation true Michael J. Valentino 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Executive Officer Director Gary Balkema 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Director Kirk Calhoun 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Director Robert Casale 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Director Natasha Giordano 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Executive Officer Director John Hadden 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Director David Luci 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Director David Jorden 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Executive Officer Gary Mossman 8285 El Rio Street Suite 130 Houston TX TEXAS 77054 Executive Officer Pharmaceuticals No Revenues 06b false 2017-06-14 false true true false 0 Raymond James & Associates, Inc. 705 None None 880 Carillon Parkway St. Petersberg FL FLORIDA 33716 CA CALIFORNIA FL FLORIDA NJ NEW JERSEY NY NEW YORK TX TEXAS VT VERMONT false Janney Montgomery Scott LLC 463 None None 1717 Arch Street Philadelphia PA PENNSYLVANIA 19103 CA CALIFORNIA FL FLORIDA NJ NEW JERSEY NY NEW YORK TX TEXAS VT VERMONT false 18191869 18191869 0 false 37 1191512 0 Sales commission reflects amount paid in connection with (i) this offering and (ii) a concurrent public offering of common stock, consisting of a $1,091,512 fee and expenses up to $100,000 (including legal fees up to $75,000). 0 No proceeds are proposed to be used for payments to such persons other than ordinary salary expenses that may be paid out of working capital. false PLx Pharma Inc. David Jorden David Jorden Acting CFO 2017-06-28

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Dipexium Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

General statement of acquisition of beneficial ownership - Nov. 20, 2017
Dipexium Pharmaceuticals, Inc. Just Filed Its Quarterly Report: Loss per share Basic... - Nov. 9, 2017
Departure of Directors or Certain - Oct. 27, 2017

Auto Refresh

Feedback